文献速递神经核医学肿瘤 PET/CT核素与放射性配体治疗

68Ga-PSMA-HBED-CC PET/CT在初治低级别与高级别胶质瘤中的摄取差异

Differential Uptake of 68Ga-PSMA-HBED-CC (PSMA-11) in Low-Grade Versus High-Grade Gliomas in Treatment-Naive Patients.
PubMed 文献 · Clin Nucl Med · 2019-01-01

结果显示所有患者胶质瘤均有 PSMA 表达,7 例胶质母细胞瘤(8 个病灶)的 PSMA 表达显著高于低级别胶质瘤,平均 SUVmax 分别为 16.93 与 2.93。

要点

  • 68Ga-PSMA-11 PET/CT 可在体内显示胶质瘤 PSMA 表达。
  • 高级别胶质瘤 PSMA SUVmax、T/B 比值及 MIB-1 PI 均高于低级别。
  • 部分患者或可从 PSMA 靶向放射性核素治疗中获益。

核心结论

  • 68Ga-HBED-CC-PSMA PET/CT 可表征胶质瘤 PSMA 表达,高级别者的 SUVmax、MIB-1 PI 与肿瘤/本底比值高于低级别。

主要发现

  • 所有患者胶质瘤均可见体内 PSMA 表达。
  • 7 例胶质母细胞瘤共 8 个病灶的平均 SUVmax 为 16.93,低级别胶质瘤为 2.93。
  • 高级别与低级别胶质瘤的平均肿瘤/本底比值分别为 13.95 与 3.42。
  • 高级别与低级别胶质瘤的平均 MIB-1 PI 分别为 17.31 与 3.3。

临床怎么用

  • 对初治胶质瘤患者,可考虑用 68Ga-PSMA-11 PET/CT 评估 PSMA 表达以辅助分级判断。
  • PSMA 高表达的高级别胶质瘤患者可能适合筛选进入 PSMA 靶向放射性核素治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE OF THE REPORT: Prostate-specific membrane antigen (PSMA) is a type II membrane glycoprotein, which is not only overexpressed in prostate cancers but also in variety of solid tumors including glioblastoma multiforme. The aim of the present study was to demonstrate PSMA expression in gliomas using Ga-PSMA-HBED-CC(PSMA 11) PET/CT. PATIENTS AND METHODS: Ten patients with initially MRI suspected and eventually histopathologically proven gliomas [8 males (age range 30-73 yr; mean age 51.8 yr); 2 females aged 39 and 55 years] were subjected preoperatively to regional brain PET scan with Ga-PSMA-11 and F-FDG PET/CT. Final histopathology of brain lesions, their MIB-1 proliferation index (MIB-1 PI) were compared with PSMA and FDG PET findings. RESULTS: FDG PET/CT showed distinct FDG uptake in high-grade gliomas, whereas low-grade gliomas were non-FDG-avid amidst physiological tracer uptake. In vivo PSMA expression was seen in all patients with glioma. Of these, the 7 patients of glioblastoma harboring 8 lesions showed significantly higher PSMA expression than those with low-grade gliomas, average SUVmax being 16.93 and 2.93, respectively. Similarly, average tumor-to-background ratios (13.95 and 3.42, respectively) and MIB-1 PI (17.31 and 3.3, respectively) were substantially more in high-grade versus low-grade gliomas. CONCLUSIONS: The results of this pilot study show that Ga-HBED-CC-PSMA PET/CT can be used to characterize the PSMA expression in gliomas, high-grade ones demonstrating higher SUVmax, MIB-1 PI tumor-to-background ratio than the low-grade ones. With these results as basis, certain patients may benefit from potential PSMA-targeted radionuclide therapy.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Verma P, Malhotra G, Goel A, et al. Differential Uptake of 68Ga-PSMA-HBED-CC (PSMA-11) in Low-Grade Versus High-Grade Gliomas in Treatment-Naive Patients. Clin Nucl Med. 2019. PMID: 30829867. doi:10.1097/RLU.0000000000002520

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。